@article {10.3844/ajmsp.2012.34.36,
article_type = {journal},
title = {In Vitro Activity of Tigecycline in the Era of NDM-1},
author = {Sureshkumar, Dorairajan and Gopalakrishnan, Ram and Thirunarayan, M.A.},
volume = {3},
year = {2012},
month = {Sep},
pages = {34-36},
doi = {10.3844/ajmsp.2012.34.36},
url = {https://thescipub.com/abstract/ajmsp.2012.34.36},
abstract = {In the current era of New Delhi Metallo-betalactamase-1 (NDM-1) infections and a dry antibiotic pipeline, managing infections caused by Multi-Drug Resistant Gram-Negative Bacterial infections (MDR-GNBs) presents a great challenge to physicians in the developing world. Tigecycline, a broad spectrum glycylcycline is a one among the few treatment options against MDR-GNBs. However it has been studied mostly in the western world, where the prevalence of MDR-GNB infections is less than the developing world. In this study, we report the in vitro activities of tigecycline and selected antimicrobials against gram-negative bacterial isolates. We evaluated the in vitro activity of tigecycline against 80 gram-negative bacterial isolates and compared its susceptibility against Cefoperazone-Sulbactam (CS), imipenem and colistin in a tertiary care hospital in South India. Tigecycline showed 100% activity against E.coli, similar to colistin and better than impenem and cefoperazone-sulbactam. However only 80% of Klebsiella pneumoniae isolates remained susceptible to tigecycline and colistin had higher in vitro activity against Acinetobacter. Tigecycline is a good option for the management of MDR E.coli and an alternative option against Acinetobacter infections in India. However the decline in susceptibility of tigecycline against K.pneumoniae is a worrisome phenomenon.},
journal = {Current Research in Microbiology},
publisher = {Science Publications}
}